VIAGRA 25 MG

Land: Israel

Sprog: engelsk

Kilde: Ministry of Health

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
07-06-2023
Produktets egenskaber Produktets egenskaber (SPC)
18-04-2021

Aktiv bestanddel:

SILDENAFIL AS CITRATE

Tilgængelig fra:

PFIZER PFE PHARMACEUTICALS ISRAEL LTD

ATC-kode:

G04BE03

Lægemiddelform:

FILM COATED TABLETS

Sammensætning:

SILDENAFIL AS CITRATE 25 MG

Indgivelsesvej:

PER OS

Recept type:

Required

Fremstillet af:

FAREVA AMBOISE, FRANCE

Terapeutisk gruppe:

SILDENAFIL

Terapeutisk område:

SILDENAFIL

Terapeutiske indikationer:

Treatment of erectile dysfunction.

Autorisation dato:

2023-06-30

Indlægsseddel

                                ةصصخملا ةيودلأا ةصاخ ،
ً
اررض ببسي دق ىرخأ ةيودأ عم ارچايڤ
ةكراشم نإ
ةلاح ثودح لاح يف .(angina pectoris ،ةيردص ةحبذ)
ردصلا ملأ جلاعل
ارچايڤ تلوانت كنأب يلديصلا وأ ة/ضرمملا
،بيبطلا علاطإ كيلع ،ةئراط ةيبط
كل ردصأ اذإ لاإ ىرخأ ةيودأ ةكراشمب
ارچايڤ لامعتسإ زوجي لا .هلوانت دعومبو
.كلذ نكمي هنأب تاميلعت بيبطلا
:ةيلاتلا ةيودلأا لوانتت تنك اذإ ارچايڤ
لامعتسإ زوجي لا
دق عونلا اذه نم ةيودأ عم ةكراشملا نلأ
،تارتنلا تارضحتسم ىمست ةيودأ
●
ةيودأ لوانتت تنك اذإ بيبطلا رشتسإ
.مدلا طغض يف ريطخ ضافخنإ ىلإ يدؤي
ملأ ،ةيردصلا ةحبذلا) ةيردصلا ةحبذلا
جلاعل ةداع لمعتست يتلا عونلا اذه نم
.(ردصلا يف
يه ةكراشملا هذه نلأ ،ليملأا تيرتن لثم
كيرتنلا ديسكأ تاحنام ىمست ةيودأ
●
.مدلا طغض يف ريطخ ضافخنإ ىلإ يدؤت دق
ً
اضيأ
فعض) يسنجلا زجعلا جلاعل (يعضوملا وأ
يومفلا ءاطعلإاب) ىرخأ ةيودأ
●
.ةعونمم ارچايڤ عم ةكراشملا ـ (باصتنلإا
ةيعولأا يف مدلا طغض عافترإ جلاعل ىرخأ
ةيودأ وأ (riociguat) تاوچيسوير
●
.ةعونمم ارچايڤ عم ةكراشملا ـ ةئرلا يف
ةيومدلا
:ةيفاضإ ةيودأ
،(تايرطفلل داضم) لوزانوكوتيك ،(ةدعملا
ةضومح ضفخل) نيديتيميس ●
.(يويح داضم) نيسيمورتيرإ
(ريڤانوتير ،ريڤانيوكاس لثم) زآيتورﭘ HIV
تاطبثم عون نم زديلإا جلاعل ةيودأ
●
رادقملا بيبطلا كل فصي نأ زئاجلا نم
.مدلا يف ارچايڤ زي
                                
                                Læs hele dokumentet
                                
                            

Produktets egenskaber

                                VIAGRA LPD CC 211122
1
S
TABLET
FILM COATED
& 100 MG
MG
50
,
25 MG
®
A
VIAGR
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
VIAGRA
®
25 mg
VIAGRA
®
50 mg
VIAGRA
®
100 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each coated tablet
contains sildenafil citrate
equivalent to 25, 50 or 100 mg of sildenafil.
Excipient with known effect
VIAGRA
®
25 mg tablets
Each tablet contains 0.9 mg lactose monohydrate
VIAGRA
®
50 mg tablets
Each tablet contains 1.7 mg lactose monohydrate
VIAGRA
®
100 mg tablets
Each tablet contains 3.5 mg lactose monohydrate
For the full list of excipients, see Section 6.1
3.
PHARMACEUTICAL FORM
Film coated tablet.
VIAGRA25 mg tablets
Blue, film coated, rounded diamond-shaped tablets, marked "PFIZER" on
one side and
"VGR 25" on the other.
VIAGRA50 mg tablets
Blue, film coated, rounded diamond-shaped tablets, marked "PFIZER" on
one side and
"VGR 50" on the other.
VIAGRA100 mg tablets
Blue, film coated, rounded diamond-shaped tablets, marked "PFIZER" on
one side and
"VGR 100" on the other.
VIAGRA LPD CC 211122
2
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
VIAGRA is indicated for the treatment of erectile dysfunction.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Sildenafil tablets are for oral administration.
USE IN ADULTS
The recommended dose is 50 mg taken as needed approximately one hour
before sexual
activity. Based on efficacy and tolerability, the dose may be
increased to 100 mg or decreased to
25 mg. The maximum recommended dose is 100 mg. The maximum
recommended dosing frequency is once per day. If VIAGRA
®
is taken with food, the onset of
activity may be delayed compared to the fasted state (see section
5.2).
Special populations
_Elderly: _
Dosage adjustments are not required in elderly patients (
≥ 65 years old)
.
R
_enal impairment _
Dosage adjustments are not required in patients with mild to moderate
renal impairment
(creatinine clearance = 30 - 80 mL/min).
Since sildenafil clearance is reduced in patients with severe renal
impairment (creat
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Indlægsseddel Indlægsseddel arabisk 07-06-2023
Indlægsseddel Indlægsseddel hebraisk 07-06-2023

Søg underretninger relateret til dette produkt